Development of novel drug delivery systems based on thiolated and PEGylated organosilica nanoparticles for cancer therapy

  • Mun, Ellina (PI)
  • Umbayev, Bauyrzhan (Other Faculty/Researcher)
  • Nurpeissova, Zhansaya (Other Faculty/Researcher)
  • Zhaisanbayeva, Balnur (PhD student/Master degree holder)

Project: MES RK

Project Details

Grant Program

Grant funding 2022-2024

Project Description

The aim of the project is to develop a novel glutathione-responsive drug delivery systems based on thiolated and PEGylated organosilica nanoparticles, study their drug release profiles in vitro, develop their toxicity and biodistribution profiles in vitro and in vivo. This will be performed by addressing the tasks below.

Project Relevance

This project is dedicated to the development of novel glutathione-responsive drug delivery system based on thiolated and PEGylated organosilica nanoparticles, to studying their toxicity profiles both in vitro and in vivo, localization in cells, in vivo biodistribution, as well as hemotoxicity, biocompatibility, drug release profiles, biodegradation and elimination providing a better understanding of their interaction with biological systems, including human blood. The toxicological properties of organosilica nanoparticles haven’t been studied properly yet, and this project will be providing an essential data for their application in biomedical and pharmaceutical fields.

Project Impact

A novel drug delivery system based on organosilica nanoparticles for cancer therapy will be developed as a result of the proposed project. The drug release kinetics, as well as toxicity, biodistribution, biocompatibility and biodegradation profiles, both in vitro and in vivo, of MPTS organosilica nanoparticles will be developed for the first time and extensively investigated.
These results will produce essential data for the application of organosilica nanoparticles as drug delivery systems in cancer therapy in biomedical and pharmaceutical fields, that is still not fully known. This will contribute greatly to understanding the behavior of organosilica nanoparticles in vivo, their biodistribution and elimination pathways, as well as their toxicity and biocompatibility, providing essential aspects towards the development of organosilica nanoparticle-based drug and gene delivery systems and bioimaging tools.
AcronymAP13068353
StatusActive
Effective start/end date1/1/2212/31/24